Table 2.
Mean % reduction from baseline to week 2 in total lesion counts (primary end‐point) for clindamycin phosphate 1.2% (CLNP)/benzoyl peroxide (BPO) 3% fixed‐dose combination gel versus combination therapy of adapalene 0.1% (ADA) + CLNP (MMRM analysis [ITT population])
| CLNP/BPO 3% (n = 172) | ADA + CLNP (n = 177) | |
|---|---|---|
| n | 169 | 176 |
| Mean (SD) | −46.3 (24.4) | −39.3 (29.3) |
| Adjusted mean (SE) | −42.2 (1.9) | −35.3 (1.9) |
| Difference vs ADA + CLNP (MMRM) | −6.83 | |
| Difference vs ADA + CLNP (unadjusted; post‐hoc) | −6.92 | |
| 95% CI for treatment difference (MMRM) | −11.88 to −1.78 | |
| 95% CI for treatment difference (unadjusted; post‐hoc) | −12.64 to −1.20 | |
| P‐value (MMRM) | 0.008 | |
| P‐value (unadjusted; post‐hoc) | 0.018 | |
ADA, adapalene; BPO, benzoyl peroxide; CI, confidence interval; CLNP, clindamycin phosphate; ITT, intent‐to‐treat; MMRM, mixed model for repeated measures SD, standard deviation; SE, standard error.